DBV Technologies S.A. (NASDAQ:DBVT) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $14.75.

A number of research analysts recently commented on DBVT shares. Lifesci Capital upgraded DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. JMP Securities reissued a "market outperform" rating and issued a $21.00 price target on shares of DBV Technologies in a research note on Thursday, June 26th. Citigroup reissued an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. Finally, The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 price target for the company in a research note on Thursday, May 29th.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Price Performance

Shares of DBVT stock traded down $0.20 on Tuesday, hitting $9.57. 60,968 shares of the stock traded hands, compared to its average volume of 18,906. The company has a market capitalization of $262.09 million, a PE ratio of -1.94 and a beta of -0.59. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $12.78. The company's fifty day moving average is $9.50 and its 200 day moving average is $7.25.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.